We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.42 | 0.35% | 969.91 | 947.27 | 980.00 | 971.86 | 952.30 | 965.58 | 444,019 | 01:00:00 |
1. Name and Address of Reporting Person * STAHL NEIL | 2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP Research and Development |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 2/26/2020 | M(1) | 25000 | A | $52.03 | 36380 | D | |||
Common Stock | 2/26/2020 | F(1) | 14651 | D | $451.89 | 21729 | D | |||
Common Stock | 2/27/2020 | S(1) | 209 | D | $435.93 (2) | 21520 | D | |||
Common Stock | 2/27/2020 | S(1) | 348 | D | $436.43 (3) | 21172 | D | |||
Common Stock | 2/27/2020 | S(1) | 480 | D | $437.41 (4) | 20692 | D | |||
Common Stock | 2/27/2020 | S(1) | 256 | D | $438.63 (5) | 20436 | D | |||
Common Stock | 2/27/2020 | S(1) | 231 | D | $439.73 (6) | 20205 | D | |||
Common Stock | 2/27/2020 | S(1) | 395 | D | $440.24 (7) | 19810 | D | |||
Common Stock | 2/27/2020 | S(1) | 264 | D | $443.67 (8) | 19546 | D | |||
Common Stock | 2/27/2020 | S(1) | 490 | D | $444.65 (9) | 19056 | D | |||
Common Stock | 2/27/2020 | S(1) | 120 | D | $445.91 (10) | 18936 | D | |||
Common Stock | 2/27/2020 | S(1) | 240 | D | $448.86 (11) | 18696 | D | |||
Common Stock | 2/27/2020 | S(1) | 236 | D | $449.53 (12) | 18460 | D | |||
Common Stock | 2/27/2020 | S(1) | 125 | D | $450.1 | 18335 | D | |||
Common Stock | 2/27/2020 | S(1) | 233 | D | $451.47 (13) | 18102 | D | |||
Common Stock | 2/27/2020 | S(1) | 130 | D | $452.08 | 17972 | D | |||
Common Stock | 2/27/2020 | S(1) | 113 | D | $453.45 | 17859 | D | |||
Common Stock | 2/27/2020 | S(1) | 102 | D | $454.58 (14) | 17757 | D | |||
Common Stock | 2/27/2020 | S(1) | 2967 | D | $455.56 (15) | 14790 | D | |||
Common Stock | 2/27/2020 | S(1) | 743 | D | $456.63 (16) | 14047 | D | |||
Common Stock | 2/27/2020 | S(1) | 141 | D | $457.27 (17) | 13906 | D | |||
Common Stock | 2/27/2020 | S(1) | 460 | D | $458.59 (18) | 13446 | D | |||
Common Stock | 2/27/2020 | S(1) | 692 | D | $459.47 (19) | 12754 | D | |||
Common Stock | 2/27/2020 | S(1) | 252 | D | $460.34 (20) | 12502 | D | |||
Common Stock | 2/27/2020 | S(1) | 614 | D | $461.24 (21) | 11888 | D | |||
Common Stock | 2/27/2020 | S(1) | 1 | D | $462.15 | 11887 | D | |||
Common Stock | 2/27/2020 | S(1) | 123 | D | $463.1 | 11764 | D | |||
Common Stock | 2/27/2020 | S(1) | 126 | D | $464.14 (22) | 11638 | D | |||
Common Stock | 2/27/2020 | S(1) | 227 | D | $465.42 (23) | 11411 | D | |||
Common Stock | 2/27/2020 | S(1) | 31 | D | $468.56 | 11380 (24) | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
STAHL NEIL 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 | EVP Research and Development |
Signatures | ||
/s/**Neil Stahl | 2/28/2020 | |
**Signature of Reporting Person | Date |
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions